Last reviewed · How we verify
Dehydroepiandrosterone, BAY86-5314 — Competitive Intelligence Brief
phase 2
Oncology, Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
Dehydroepiandrosterone, BAY86-5314 (Dehydroepiandrosterone, BAY86-5314) — Bayer. Dehydroepiandrosterone is a naturally occurring steroid hormone that has been investigated for its potential therapeutic effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dehydroepiandrosterone, BAY86-5314 TARGET | Dehydroepiandrosterone, BAY86-5314 | Bayer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dehydroepiandrosterone, BAY86-5314 CI watch — RSS
- Dehydroepiandrosterone, BAY86-5314 CI watch — Atom
- Dehydroepiandrosterone, BAY86-5314 CI watch — JSON
- Dehydroepiandrosterone, BAY86-5314 alone — RSS
Cite this brief
Drug Landscape (2026). Dehydroepiandrosterone, BAY86-5314 — Competitive Intelligence Brief. https://druglandscape.com/ci/dehydroepiandrosterone-bay86-5314. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab